For the roughly 160,000 people diagnosed with multiple myeloma each year worldwide, the standard expectation has been indefinite drug therapy — a regimen that carries cumulative toxicity, cost, and quality-of-life burdens. A Phase III trial now challenges that assumption directly, suggesting that a defined two-year course may be sufficient to preserve survival in a key patient subset.
The trial enrolled 516 patients with standard-risk newly diagnosed multiple myeloma who were not candidates for upfront autologous stem-cell transplantation. Following induction with a proteasome inhibitor–lenalidomide combination, patients were randomized to either continuous lenalidomide maintenance or a fixed two-year course. After a median follow-up of 86 months — nearly seven and a half years — overall survival was statistically indistinguishable between the two arms: 68.6% versus 69.0% at seven years, with 80 deaths in each group and a hazard difference of just -0.4 percentage points. Progression-free survival at seven years favored continuous therapy (36.1% vs. 29.7%), though this did not translate into a mortality difference within the observation window.
This finding carries substantial clinical weight. Lenalidomide is an immunomodulatory agent associated with secondary malignancies, persistent cytopenias, and significant financial toxicity when used indefinitely. The trial was adequately powered to detect a meaningful survival difference — a 50% increase in median survival — and found none, making the null result credible rather than merely underpowered. That said, the population is carefully circumscribed: standard-risk patients forgoing transplant, which limits generalizability to high-risk myeloma or transplant-eligible cohorts. The progression-free survival gap is also worth monitoring over longer follow-up, as late relapses could yet produce a survival signal. For now, this is potentially practice-changing evidence that fixed-duration therapy may spare patients years of unnecessary treatment without compromising longevity.